Ilyang Pharmaceutical launches ‘Supect’ as a primary treatment of leukemia

‘Supect(generic name: radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical(CEO Dong-yeon Kim), will be launched as the ‘primary treatment’ on the 1^st of February.

Supect, which has proceeded the change of the insurance benefit standard after acquiring approval as a primary treatment on 27 Oct. 2015, will have active marketing for the market expanded more than 10 ...